Psilocybin For Treatment Resistant Depression

Therapeutic Goods | Claims Management

Psilocybin for treatment-resistant depression is now legally prescribable in Australia, and psilocybin therapy workers compensation claims are a question of when, not if. Since 1 July 2023, authorised psychiatrists have been able to prescribe psilocybin for treatment-resistant depression under the TGA Authorised Prescriber scheme. This guide explains what claims managers need to know to verify prescriptions, assess coverage, and make defensible decisions on invoices involving psilocybin-assisted therapy.

What Changed on 1 July 2023?

Following a 2022 public consultation, the TGA announced on 3 February 2023 that psilocybin would be reclassified from Schedule 9 Prohibited Substance to Schedule 8 Controlled Drug, with the change taking effect on 1 July 2023. The rescheduling applies exclusively to treatment-resistant depression. For all other indications, psilocybin remains Schedule 9 and cannot be prescribed under any legal pathway.

Australia was the first country in the world to make this reclassification, ahead of any comparable move by the United States FDA or European regulators. The clinical evidence supporting the decision came primarily from Phase 2 and Phase 3 trials conducted internationally, with Australian researchers also contributing to the evidence base through university and hospital-affiliated programs.

For claims managers, the practical consequence is that a psilocybin invoice from an authorised psychiatrist is a legitimate document that cannot simply be rejected on the basis that the substance is prohibited. It requires proper assessment.

How Does the TGA Authorised Prescriber Pathway Work for Psilocybin?

The prescribing pathway is among the most controlled in Australian pharmaceutical regulation. A psychiatrist seeking to prescribe psilocybin must first obtain ethics approval from a Human Research Ethics Committee registered with the National Health and Medical Research Council. They must then apply separately to the TGA for individual Authorised Prescriber status, demonstrating they have the required training, competency, and access to an approved clinical treatment protocol.

Uptake of this pathway has been deliberately slow. As of August 2025, only 12 psychiatrists appeared in the RANZCP self-nominated directory as authorised to prescribe psilocybin. Mind Medicine Australia reported 13 Authorised Prescribers across five Australian states in September 2025. A separate study noted that access is concentrated in major urban academic institutions, amplifying geographic and socioeconomic disparities in who can actually receive the treatment.

From January 2024 through September 2025, the TGA's own aggregated data showed 47 patients had received psilocybin treatment through the Authorised Prescriber scheme, with zero serious adverse events reported. This is a tiny patient cohort relative to the scale of treatment-resistant depression in Australia.

New quality standards for psilocybin products were established by Therapeutic Goods Orders in 2024, taking effect in January 2025. These set mandatory requirements for product purity, GMP compliance, and testing. The specific molecule must be derived from Psilocybe cubensis and meet 80 to 120 percent assay limits. These product standards add a further compliance layer that legitimate invoices must satisfy.

Is Treatment-Resistant Depression a Compensable Condition in Workers Compensation?

Depression, including treatment-resistant depression, can be a compensable psychological injury where it meets scheme eligibility criteria. To be compensable, the condition must be a recognised clinical diagnosis, the work must be a major contributing factor, and the injury must not arise from reasonable management action.

Treatment-resistant depression as a specific clinical classification adds complexity to a claims assessment. It is defined as depression that has not responded to at least two adequate trials of different antidepressant medications. This implies a pre-existing or long-standing depressive illness, which may raise questions about the causal contribution of work versus other life factors, and whether prior treatment history was related to the claim.

Claims managers should seek an independent psychiatric opinion before making any determination on compensability where treatment-resistant depression is the primary diagnosis. The causal connection between the diagnosis and the compensable event must be established before any assessment of psilocybin therapy costs is warranted.

What Does Psilocybin-Assisted Therapy Actually Involve?

Psilocybin-assisted therapy is not a conventional pharmacological treatment. It combines one to three supervised drug sessions, each lasting four to six hours in a controlled clinical environment, with preparatory psychotherapy sessions and post-session integration therapy. The psilocybin is used to facilitate a psychotherapeutic process, not as a standalone antidepressant.

The full course of treatment is resource-intensive. Australian private clinic pricing for a complete psilocybin therapy course, including drug sessions and the surrounding psychotherapy, typically ranges from $10,000 to $25,000. There is no PBS listing and no Medicare rebate for the drug or the therapy sessions, so these costs fall entirely outside standard scheme reimbursement unless specifically authorised by the insurer.

In October 2025, Medibank, Australia's largest private health insurer, expanded its AUD $10 million psychotherapy program to include psilocybin for treatment-resistant depression, building on its earlier coverage of MDMA for PTSD. This represents the most significant insurer movement toward covering psychedelic-assisted therapies in Australia, though it applies to private health rather than workers compensation or CTP schemes.

How Should a Claims Manager Assess a Psilocybin Invoice?

A structured assessment process is essential. The recommended sequence is as follows.

Verify prescriber authority as the first step. Confirm that the prescribing psychiatrist holds active TGA Authorised Prescriber status specifically for psilocybin. Given the extremely small number of authorised prescribers nationally, this is a straightforward but critical check. The TGA publishes this data and it should be confirmed against the actual prescriber named on the invoice.

Confirm the indication is treatment-resistant depression. Psilocybin is authorised for this indication only. A prescription for any other condition, including anxiety, PTSD, or general depression that does not meet the treatment-resistant threshold, falls outside the approved pathway.

Assess prior treatment history. The treatment-resistant classification itself implies that prior treatments have failed, but claims managers should request documented evidence of prior medication trials and psychological treatment to confirm the diagnosis is appropriately characterised and was not artificially constructed to access the psilocybin pathway.

Confirm causal connection to the compensable claim. Treatment-resistant depression as a diagnosis raises inherent questions about chronicity and pre-existing conditions. Independent psychiatric assessment of the causal relationship between the depressive illness and the workplace injury or CTP event is essential.

Key Takeaways

• Psilocybin is no longer a Schedule 9 prohibited substance for all purposes. Since 1 July 2023, it is a Schedule 8 Controlled Drug legally prescribable for treatment-resistant depression by TGA Authorised Psychiatrists only.
• The prescribing pathway is extremely narrow. Only 12 to 13 psychiatrists held active Authorised Prescriber status for psilocybin nationally as of late 2025. Any prescription from outside this group is not legally valid.
• Treatment-resistant depression as a compensable condition requires careful causal analysis. The long-standing and complex nature of the diagnosis creates additional evidentiary obligations for claims managers.
• A full psilocybin therapy course costs $10,000 to $25,000. There is no PBS listing or Medicare rebate. These costs require specific authorisation and independent clinical review before any approval is given.
• Medibank's AUD $10M expansion to cover psilocybin for treatment-resistant depression signals the direction of insurer thinking, even if workers compensation schemes are not yet subject to that precedent.
• An independent clinical review from a pharmacy assessor or medical specialist is essential for any claim involving psilocybin-assisted therapy before a reasonable and necessary determination is made.

Frequently Asked Questions

Primary source: Therapeutic Goods Administration (TGA) -- MDMA and Psilocybine Hub and Authorised Prescriber Scheme guidance, tga.gov.au